{"id":"intravitreal-aflibercept-injection","safety":{"commonSideEffects":[{"rate":null,"effect":"Conjunctival hemorrhage"},{"rate":null,"effect":"Eye pain"},{"rate":null,"effect":"Floaters"},{"rate":null,"effect":"Intraocular pressure elevation"},{"rate":"0.05–0.1","effect":"Endophthalmitis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Aflibercept functions as a fusion protein combining VEGF-binding domains from VEGF receptors 1 and 2 with the Fc portion of human IgG1. When injected intravitreally, it acts as a molecular trap, sequestering circulating VEGF and PlGF in the vitreous and preventing their binding to VEGFR1 and VEGFR2 on endothelial cells. This inhibition of VEGF signaling reduces pathological neovascularization, vascular permeability, and inflammation associated with retinal diseases.","oneSentence":"Aflibercept is a soluble decoy receptor that binds vascular endothelial growth factor (VEGF) and placental growth factor (PlGF), preventing their interaction with endogenous receptors and reducing abnormal blood vessel growth in the eye.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:50:01.761Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Neovascular (wet) age-related macular degeneration"},{"name":"Macular edema following retinal vein occlusion"},{"name":"Diabetic macular edema"},{"name":"Diabetic retinopathy"}]},"trialDetails":[{"nctId":"NCT07496567","phase":"PHASE2, PHASE3","title":"A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003)","status":"NOT_YET_RECRUITING","sponsor":"EyeBiotech Ltd.","startDate":"2026-04-30","conditions":"Macular Degeneration, Age-Related Macular Degeneration, Choroidal Neovascularization","enrollment":960},{"nctId":"NCT06864988","phase":"PHASE3","title":"4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration","status":"ACTIVE_NOT_RECRUITING","sponsor":"4D Molecular Therapeutics","startDate":"2025-03-03","conditions":"Macular Neovascularization Secondary to Age-Related Macular Degeneration","enrollment":480},{"nctId":"NCT07118670","phase":"PHASE4","title":"High Dose Eylea for Proliferative Diabetic Retinopathy Outcomes","status":"ACTIVE_NOT_RECRUITING","sponsor":"Edward Wood, MD","startDate":"2025-12-08","conditions":"Proliferative Diabetic Retinopathy (PDR)","enrollment":40},{"nctId":"NCT06893965","phase":"NA","title":"Acute Intra Ocular Pressure Monitoring After Aflibercept 8mg/0.07mL","status":"RECRUITING","sponsor":"Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer","startDate":"2025-07-08","conditions":"Macular Diseases","enrollment":100},{"nctId":"NCT07481500","phase":"NA","title":"Speculum-Free Intravitreal Injection Using Cotton-Tipped Applicator Retraction: A Randomized Trial of Pain, Procedure Time, Patient Satisfaction, and Safety","status":"NOT_YET_RECRUITING","sponsor":"Jakkrit Juhong","startDate":"2026-06","conditions":"Neovascular Age-Related Macular Degeneration (nAMD), Diabetic Macular Edema, Retinal Vein Occlusion","enrollment":120},{"nctId":"NCT07449936","phase":"PHASE3","title":"COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME","status":"RECRUITING","sponsor":"EyePoint Pharmaceuticals, Inc.","startDate":"2026-02-26","conditions":"Diabetic Macular Edema, DME, Diabetic Macular Edema (DME)","enrollment":240},{"nctId":"NCT07362927","phase":"EARLY_PHASE1","title":"Safety and Efficacy Evaluation of LX111 Gene Therapy in DME Patients","status":"RECRUITING","sponsor":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2026-03","conditions":"Diabetic Macular Edema (DME)","enrollment":32},{"nctId":"NCT06929143","phase":"","title":"A Study to Learn More About the Use of Aflibercept in Routine Medical Practice in Japanese Participants With Neovascular Age-related Macular Degeneration and Diabetic Macular Edema","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bayer","startDate":"2025-04-14","conditions":"Neovascular Age-related Macular Degeneration (nAMD), Diabetic Macular Edema (DME)","enrollment":3000},{"nctId":"NCT06196840","phase":"PHASE2","title":"Safety and Efficacy of LX102 Gene Therapy in Patients With Neovascular Age-related Macular Degeneration (nAMD) (VENUS)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Innostellar Biotherapeutics Co.,Ltd","startDate":"2024-01-24","conditions":"Neovascular Age-Related Macular Degeneration","enrollment":50},{"nctId":"NCT07449923","phase":"PHASE3","title":"CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME","status":"RECRUITING","sponsor":"EyePoint Pharmaceuticals, Inc.","startDate":"2026-02-09","conditions":"Diabetic Macular Edema, DME, Diabetic Macular Edema (DME)","enrollment":240},{"nctId":"NCT06668064","phase":"PHASE3","title":"A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUGANO) Primary Efficacy Will be Determined at Week 56","status":"ACTIVE_NOT_RECRUITING","sponsor":"EyePoint Pharmaceuticals, Inc.","startDate":"2024-10-22","conditions":"Wet Age Related Macular Degeneration, wAMD","enrollment":400},{"nctId":"NCT06683742","phase":"PHASE3","title":"A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56","status":"ACTIVE_NOT_RECRUITING","sponsor":"EyePoint Pharmaceuticals, Inc.","startDate":"2024-11-27","conditions":"Wet Age Related Macular Degeneration, wAMD","enrollment":400},{"nctId":"NCT04519619","phase":"","title":"Study to Learn More About Safety of Aflibercept Injection in Japanese Patients With Neovascular Glaucoma (NVG)","status":"RECRUITING","sponsor":"Bayer","startDate":"2020-11-27","conditions":"Neovascular Glaucoma","enrollment":480},{"nctId":"NCT07438119","phase":"PHASE4","title":"Efficacy Comparison of DExamethasone Intravitreal Implant Combined With Aflibercept Versus Aflibercept Monotherapy in Treatment-naïve Inflammatory Diabetic Macular Edema Patients","status":"NOT_YET_RECRUITING","sponsor":"Kun Liu","startDate":"2026-03-15","conditions":"Diabetic Macular Edema (DME)","enrollment":114},{"nctId":"NCT07440225","phase":"PHASE2, PHASE3","title":"A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002)","status":"NOT_YET_RECRUITING","sponsor":"EyeBiotech Ltd.","startDate":"2026-03-31","conditions":"Macular Degeneration, Age-Related Macular Degeneration, Choroidal Neovascularization","enrollment":960},{"nctId":"NCT07434713","phase":"","title":"EarLy Treatment Response in nEoVascular Macular Degeneration With Eylea 8mg: ELEV8 A Prospective Observational Open Label Study Investigating the Fluid Dynamics During Early Response to Aflibercept 8mg in Patients With Exudative Age-related Macular Degeneration (AMD).","status":"RECRUITING","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2025-07-14","conditions":"Age-Related Macular Degeneration (AMD)","enrollment":50},{"nctId":"NCT07390253","phase":"","title":"Switch From 2mg Aflibercept to 8mg Aflibercept in Patients With Neovascular Age-related Macular Degeneration","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vienna Institute for Research in Ocular Surgery","startDate":"2024-09-18","conditions":"Neovascular (Wet) Age-Related Macular Degeneration","enrollment":50},{"nctId":"NCT05197270","phase":"PHASE1, PHASE2","title":"4D-150 in Patients With Neovascular (Wet) Age-Related Macular Degeneration","status":"RECRUITING","sponsor":"4D Molecular Therapeutics","startDate":"2021-12-09","conditions":"Neovascular (Wet) Age-Related Macular Degeneration","enrollment":215},{"nctId":"NCT06550011","phase":"PHASE1, PHASE2","title":"Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Intravitreal (IVT) Injection of ABI-110 (AAV2.N54-VEGF Trap) in Subjects With Neovascular (Wet) Age-Related Macular Degeneration (wAMD), Including Symptomatic Macular Polypoidal Choroidal Vasculopathy (PCV)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Avirmax Biopharma Inc","startDate":"2024-08-07","conditions":"Neovascular (Wet) AMD","enrollment":18},{"nctId":"NCT07064759","phase":"PHASE3","title":"Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration","status":"RECRUITING","sponsor":"4D Molecular Therapeutics","startDate":"2025-07-22","conditions":"Neovascular Age-Related Macular Degeneration (nAMD)","enrollment":480},{"nctId":"NCT04663750","phase":"PHASE3","title":"Vitrectomy, Subretinal Tissue Plasminogen Activator (TPA) and Intravitreal Gas for Submacular Haemorrhage Secondary to Exudative (Wet) Age-related Macular Degeneration (TIGER).","status":"RECRUITING","sponsor":"King's College Hospital NHS Trust","startDate":"2021-04-16","conditions":"Eye Diseases, Macular Degeneration, Wet, Sub-Macular Hemorrhage","enrollment":210},{"nctId":"NCT07375901","phase":"NA","title":"the Blood-Aqeous Barrier During Anti-Angiogenic Therapy in Exudative Age-Related Macular Degeneration","status":"COMPLETED","sponsor":"The Filatov Institute of Eye Diseases and Tissue Therapy","startDate":"2021-03-25","conditions":"AMD","enrollment":30},{"nctId":"NCT07365371","phase":"PHASE4","title":"A Prospective, Multicenter, Open-label, Randomized Clinical Trial to Evaluate the Efficacy, Durability, and Safety of Aflibercept 8mg in Different Treatment Regimens in Chinese Patients With Polypoidal Choroidal Vasculopathy (PCV)","status":"NOT_YET_RECRUITING","sponsor":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2026-01-01","conditions":"Polypoidal Choroidal Vasculopathy (PCV), Neovascular Age Related Macular Degeneration (AMD)","enrollment":174},{"nctId":"NCT03845049","phase":"PHASE3","title":"Comparative Multicenter Randomized Study of Aflibercept Versus Placebo in Macular Telangiectasia Type 1","status":"TERMINATED","sponsor":"Centre Hospitalier Universitaire Dijon","startDate":"2019-07-03","conditions":"Macular Telangiectasia","enrollment":16},{"nctId":"NCT07338097","phase":"NA","title":"Comparison of Bevacizumab and Aflibercept in Treatment of Diabetic Macular Edema","status":"ENROLLING_BY_INVITATION","sponsor":"CMH Multan Institute of Medical Sciences","startDate":"2025-09-07","conditions":"Diabetic Macular Edema (DME)","enrollment":116},{"nctId":"NCT05769153","phase":"PHASE1, PHASE2","title":"Study of AR-14034 in Participants With Neovascular Age-Related Macular Degeneration (nAMD)","status":"RECRUITING","sponsor":"Alcon Research","startDate":"2023-12-06","conditions":"Neovascular Age-related Macular Degeneration (nAMD)","enrollment":140},{"nctId":"NCT06422507","phase":"PHASE3","title":"A Study to Learn More About How Well 8 Milligram Aflibercept Works and How Safe it is in Chinese Participants With Diabetic Macular Edema","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bayer","startDate":"2024-05-29","conditions":"Diabetic Macular Edema","enrollment":333},{"nctId":"NCT07301775","phase":"PHASE4","title":"Comparing Single Versus Multiple Anti-VEGF Injections in Diabetic Patients Undergoing Cataract Surgery","status":"NOT_YET_RECRUITING","sponsor":"Ahmad Zeeshan Jamil","startDate":"2026-01-01","conditions":"Diabetic Retinopathy (DR), Diabetic Macular Edema (DME), Cataract","enrollment":166},{"nctId":"NCT03006081","phase":"PHASE2","title":"The Efficacy of Intravitreal Aflibercept Injection in Improvement of Retinal Nonperfusion in Diabetic Retinopathy","status":"COMPLETED","sponsor":"Asan Medical Center","startDate":"2016-04-14","conditions":"Diabetic Retinopathy","enrollment":38},{"nctId":"NCT04101877","phase":"PHASE2","title":"The Sahlgrenska Anti-VEGF Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vastra Gotaland Region","startDate":"2020-09-03","conditions":"Neovascular Age-related Macular Degeneration","enrollment":402},{"nctId":"NCT03941587","phase":"NA","title":"Comparing Intravitreal Aflibercept Monotherapy vs Aflibercept Combined With Reduced Fluence PDT in PCV Treatment","status":"COMPLETED","sponsor":"Singapore National Eye Centre","startDate":"2021-02-01","conditions":"Polypoidal Choroidal Vasculopathy","enrollment":60},{"nctId":"NCT02462889","phase":"PHASE2","title":"IAI Versus Sham as Prophylaxis Against Conversion to Neovascular AMD","status":"COMPLETED","sponsor":"Jeffrey S Heier","startDate":"2015-06","conditions":"Age-Related Macular Degeneration","enrollment":128},{"nctId":"NCT04522167","phase":"PHASE3","title":"Efficacy and Safety of the Aflibercept FYB203 Biosimilar in Comparison to Eylea® in Patients With Neovascular Age-Related Macular Degeneration","status":"COMPLETED","sponsor":"Bioeq GmbH","startDate":"2020-07-21","conditions":"Neovascular Age-related Macular Degeneration","enrollment":434},{"nctId":"NCT06591598","phase":"PHASE4","title":"A Study to Learn About the Blood Levels of Aflibercept When High-dose Aflibercept is Injected in Both Eyes of Participants With Diabetic Macular Edema or Neovascular Age-related Macular Degeneration","status":"COMPLETED","sponsor":"Bayer","startDate":"2024-09-02","conditions":"Diabetic Macular Edema, Neovascular Age-related Macular Degeneration","enrollment":51},{"nctId":"NCT06116890","phase":"PHASE2","title":"Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular Degeneration","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kyowa Kirin Co., Ltd.","startDate":"2024-01-31","conditions":"Neovascular Age-Related Macular Degeneration (nAMD)","enrollment":180},{"nctId":"NCT06116916","phase":"PHASE2","title":"Study to Assess the Efficacy & Safety of KHK4951 in Patients With Diabetic Macular Edema","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kyowa Kirin Co., Ltd.","startDate":"2024-01-09","conditions":"Diabetic Macular Edema (DME)","enrollment":150},{"nctId":"NCT06556368","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAK","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kodiak Sciences Inc","startDate":"2024-08-23","conditions":"Wet Age-related Macular Degeneration","enrollment":675},{"nctId":"NCT06491914","phase":"PHASE3","title":"A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2024-07-24","conditions":"Neovascular Age-Related Macular Degeneration, Diabetic Macular Edema","enrollment":1118},{"nctId":"NCT05381948","phase":"PHASE2","title":"Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD)","status":"COMPLETED","sponsor":"EyePoint Pharmaceuticals, Inc.","startDate":"2022-06-30","conditions":"Wet Age-related Macular Degeneration","enrollment":161},{"nctId":"NCT05407636","phase":"PHASE3","title":"Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD","status":"RECRUITING","sponsor":"AbbVie","startDate":"2022-01-13","conditions":"AMD, nAMD, Wet Age-related Macular Degeneration","enrollment":660},{"nctId":"NCT03712904","phase":"PHASE2","title":"Stereotactic Body Radiation Therapy and Aflibercept in Treating Patients With Uveal Melanoma","status":"TERMINATED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","startDate":"2019-08-09","conditions":"Uveal Melanoma","enrollment":3},{"nctId":"NCT05930561","phase":"PHASE2","title":"4D-150 in Patients With Diabetic Macular Edema","status":"ACTIVE_NOT_RECRUITING","sponsor":"4D Molecular Therapeutics","startDate":"2023-08-09","conditions":"Diabetic Macular Edema, Diabetic Retinopathy","enrollment":72},{"nctId":"NCT06850571","phase":"PHASE4","title":"Aflibercept and Bevacizumab for Diabetic Maculopathies","status":"RECRUITING","sponsor":"Al-Mustansiriyah University","startDate":"2025-02-20","conditions":"Diabetic Maculopathy","enrollment":102},{"nctId":"NCT04270747","phase":"PHASE3","title":"A Study to Understand Effectiveness and Safety of ABP 938 Compared to Aflibercept (Eylea®) in Patients Suffering With Neovascular Age-related Macular Degeneration [Neovascular (Wet) AMD]","status":"COMPLETED","sponsor":"Amgen","startDate":"2020-06-22","conditions":"Neovascular (Wet) Age-related Macular Degeneration (AMD)","enrollment":576},{"nctId":"NCT05511038","phase":"PHASE4","title":"A Study to Learn How Safe the Study Drug Intravitreal (Given by an Injection Into the Eye) Aflibercept is in Participants in India With Diabetic Macular Edema","status":"COMPLETED","sponsor":"Bayer","startDate":"2022-08-26","conditions":"Diabetic Macular Edema","enrollment":100},{"nctId":"NCT04423718","phase":"PHASE3","title":"Study of the Effects of High Dose Aflibercept Injected Into the Eye of Patients With an Age-related Disorder That Causes Loss of Vision Due to Growth of Abnormal Blood Vessels at the Back of the Eye","status":"COMPLETED","sponsor":"Bayer","startDate":"2020-08-11","conditions":"Neovascular Age-Related Macular Degeneration","enrollment":1011},{"nctId":"NCT05536973","phase":"PHASE2","title":"Safety and Efficacy of ADVM-022 in Treatment-Experienced Patients With Neovascular Age-related Macular Degeneration [LUNA]","status":"ACTIVE_NOT_RECRUITING","sponsor":"Adverum Biotechnologies, Inc.","startDate":"2022-08-23","conditions":"Neovascular Age-related Macular Degeneration","enrollment":69},{"nctId":"NCT02556229","phase":"PHASE2","title":"Study Evaluating the Efficacy of Aflibercept for the Treatment of Inflammatory CNV in Young Patients (ALINEA).","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2016-06","conditions":"Inflammatory Choroidal Neovascularization","enrollment":20},{"nctId":"NCT02257502","phase":"PHASE2","title":"Study Evaluating the Efficacy of Aflibercept for the Treatment of NVCI in Young Patients","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2015-07-06","conditions":"Idiopathic Choroidal Neovascularization","enrollment":20},{"nctId":"NCT06011798","phase":"PHASE2","title":"Assess the Efficacy and Safety of Repeat Intravitreal Injections of Foselutoclax (UBX1325) in Patients With DME (ASPIRE)","status":"COMPLETED","sponsor":"Unity Biotechnology, Inc.","startDate":"2023-08-23","conditions":"Diabetic Macular Edema, Retinal Disease, Macular Edema","enrollment":52},{"nctId":"NCT04757636","phase":"PHASE3","title":"OPT-302 With Aflibercept in Neovascular Age-related Macular Degeneration (nAMD)","status":"TERMINATED","sponsor":"Opthea Limited","startDate":"2021-03-12","conditions":"Neovascular Age-related Macular Degeneration","enrollment":998},{"nctId":"NCT07096713","phase":"NA","title":"Brolucizumab Versus Aflibercept on Visual and Anatomical Outcomes in Diabetic Macular Edema","status":"COMPLETED","sponsor":"Benha University","startDate":"2024-01-01","conditions":"Anti-VEGF Therapy","enrollment":38},{"nctId":"NCT05891548","phase":"PHASE2","title":"Study to Evaluate Suprachoroidally Administered CLS-AX in the Treatment of Neovascular Age-Related Macular Degeneration","status":"COMPLETED","sponsor":"Clearside Biomedical, Inc.","startDate":"2023-05-31","conditions":"Neovascular Age-related Macular Degeneration","enrollment":60},{"nctId":"NCT03823287","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (TENAYA)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2019-02-19","conditions":"Wet Macular Degeneration","enrollment":671},{"nctId":"NCT03823300","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (LUCERNE)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2019-03-11","conditions":"Wet Macular Degeneration","enrollment":658},{"nctId":"NCT03622580","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema (YOSEMITE)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2018-09-05","conditions":"Diabetic Macular Edema","enrollment":940},{"nctId":"NCT03622593","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2018-10-09","conditions":"Diabetic Macular Edema","enrollment":951},{"nctId":"NCT06845163","phase":"PHASE2","title":"Randomized Clinical Trial to Evaluate the Effect of Dapagliflozin in Patients With Diabetic Macular Edema","status":"RECRUITING","sponsor":"Alexandria University","startDate":"2025-02-08","conditions":"Diabetic Macular Edema, Center-involved Diabetic Macular Edema","enrollment":56},{"nctId":"NCT06495918","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular Degeneration","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ocular Therapeutix, Inc.","startDate":"2024-11-27","conditions":"Neovascular Age-related Macular Degeneration","enrollment":825},{"nctId":"NCT07009574","phase":"","title":"The Treatment Burden of Myopic Choroidal Neovascularization","status":"NOT_YET_RECRUITING","sponsor":"Policlinico Gaspare Rodolico - San Marco Catania","startDate":"2025-06-01","conditions":"Myopic Choroidal Neovascularisation, Anti-VEGF Treatment, Burden","enrollment":100},{"nctId":"NCT05989126","phase":"PHASE3","title":"Study to Evaluate an 8 mg Aflibercept (EYLEA®) Prefilled Syringe (PFS)","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2024-04-15","conditions":"Diabetic Macular Edema (DME), Neovascular Age-Related Macular Degeneration (nAMD)","enrollment":35},{"nctId":"NCT05662410","phase":"PHASE4","title":"Choroidal Morphology Changes After Aflibercept Therapy in Pachychoroid Neovasculopathy","status":"COMPLETED","sponsor":"Kim's Eye Hospital","startDate":"2022-12-26","conditions":"Pachychoroid Neovasculopathy","enrollment":30},{"nctId":"NCT04793100","phase":"NA","title":"Spontaneous Retinal Artery Pulses (SPARs) as a Prognostic Determinant of Central Retinal Vein Occlusions (CRVO) in Patients With or Without Intravitreal Aflibercept Injections","status":"COMPLETED","sponsor":"Fondation Ophtalmologique Adolphe de Rothschild","startDate":"2021-03-24","conditions":"Central Retinal Vein Occlusion","enrollment":60},{"nctId":"NCT06929507","phase":"NA","title":"Impact of Intravitreal Faricimab on Renal Function in Diabetic Patients","status":"RECRUITING","sponsor":"University Hospital, Alexandroupolis","startDate":"2025-03-10","conditions":"Renal Function Disorder, Diabetic Macular Edema (DME), Neovascular Age Related Macular Degeneration","enrollment":60},{"nctId":"NCT03397264","phase":"PHASE1, PHASE2","title":"A Dose Ranging Study of OPT-302 With Aflibercept for Persistent Diabetic Macular Edema","status":"COMPLETED","sponsor":"Opthea Limited","startDate":"2018-01-16","conditions":"Diabetic Macular Edema","enrollment":153},{"nctId":"NCT06223958","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (Axitinib Implant) in Subjects With Neovascular Age-Related Macular Degeneration","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ocular Therapeutix, Inc.","startDate":"2024-01-29","conditions":"Neovascular Age-Related Macular Degeneration","enrollment":344},{"nctId":"NCT06470373","phase":"PHASE3","title":"A Phase 3 Clinical Trial to Compare RBS-001 to Eylea® in Subjects With Neovascular Age-Related Macular Degeneration","status":"NOT_YET_RECRUITING","sponsor":"Rophibio, Inc.","startDate":"2025-07","conditions":"Neovascular Age-related Macular Degeneration (nAMD)","enrollment":434},{"nctId":"NCT03585556","phase":"PHASE1","title":"AAVCAGsCD59 for the Treatment of Wet AMD","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2018-09-13","conditions":"Wet Age-related Macular Degeneration","enrollment":25},{"nctId":"NCT03172299","phase":"PHASE3","title":"Prevention of Neovascular Glaucoma by Intravitreal Injections of Anti-VEGF in Patients Treated with Proton Therapy for a Large Choroidal Melanoma","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Nice","startDate":"2017-06-08","conditions":"Ocular Melanoma","enrollment":57},{"nctId":"NCT06879301","phase":"EARLY_PHASE1","title":"Effectiveness of Intravitreal Injection of Aflibercept 8 mg in Resistant Diabetic Macular Edema, Retinal Vein Occlusion and Myopic Choroidal Neovascularisation Patients","status":"NOT_YET_RECRUITING","sponsor":"Tanta University","startDate":"2025-10-19","conditions":"Diabetic Macular Edema (DME), Retinal Vein Occlusion (RVO), Myopic Choroidal Neovascularisation","enrollment":60},{"nctId":"NCT06878573","phase":"","title":"Change in Ocular Perfusion After Intravitreal Anti-VEGF in Patients with Age-related Maculopathy or Diabetic Macula Edema","status":"COMPLETED","sponsor":"Augenabteilung Allgemeines Krankenhaus Linz","startDate":"2023-11-22","conditions":"Age Related Macular Degeneration, Diabetic Macular Edema","enrollment":36},{"nctId":"NCT05571267","phase":"PHASE2","title":"Safety Study of Zimura in Combination With Anti-VEGF Therapy in Patients With Neovascular AMD","status":"TERMINATED","sponsor":"IVERIC bio, Inc.","startDate":"2016-10-20","conditions":"Neovascular Age-Related Macular Degeneration","enrollment":1},{"nctId":"NCT05972473","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of IBI302 in Subjects With nAMD","status":"ACTIVE_NOT_RECRUITING","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2023-09-21","conditions":"Neovascular Age-related Macular Degeneration","enrollment":600},{"nctId":"NCT06099184","phase":"PHASE2","title":"Study of EYP-1901 in Patients With Diabetic Macular Edema (DME)","status":"COMPLETED","sponsor":"EyePoint Pharmaceuticals, Inc.","startDate":"2024-01-15","conditions":"Diabetic Macular Edema","enrollment":27},{"nctId":"NCT06839339","phase":"PHASE2","title":"Efficacy and Safety of AL-001 Ophthalmic Injection in Subjects with WAMD","status":"NOT_YET_RECRUITING","sponsor":"Beijing Anlong Biopharmaceutical Co., Ltd.","startDate":"2025-02-18","conditions":"Wet Age-related Macular Degeneration (wAMD)","enrollment":40},{"nctId":"NCT06132035","phase":"PHASE1","title":"Study to Evaluate the Safety of CG-P5 Peptide Eye Drops in Patients Diagnosed With Age-related Wet Macular Degeneration","status":"RECRUITING","sponsor":"Caregen Co. Ltd.","startDate":"2023-12-22","conditions":"Age-related Wet Macular Degeneration","enrollment":45},{"nctId":"NCT05640895","phase":"","title":"Intravitreal Injection Site and Perceived Pain","status":"COMPLETED","sponsor":"The University of Texas Medical Branch, Galveston","startDate":"2022-11-14","conditions":"Pain","enrollment":53},{"nctId":"NCT04708145","phase":"PHASE4","title":"Long-Term Efficacy and Safety of Intravitreal Aflibercept Injections for the Treatment of Diabetic Retinopathy for Subjects Who Completed the 2-Year PANORAMA Trial","status":"COMPLETED","sponsor":"Greater Houston Retina Research","startDate":"2021-06-01","conditions":"Diabetic Retinopathy","enrollment":41},{"nctId":"NCT06610747","phase":"NA","title":"Home- vs Hospital-based Care of Anti-VEGF Treatment for Diabetic Macular Edema: Non-inferiority RCT","status":"RECRUITING","sponsor":"Zhongshan Ophthalmic Center, Sun Yat-sen University","startDate":"2024-10-28","conditions":"Diabetic Macular Edema","enrollment":308},{"nctId":"NCT02434328","phase":"PHASE3","title":"Efficacy and Safety of RTH258 Versus Aflibercept - Study 2","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2015-07-28","conditions":"Neovascular Age-Related Macular Degeneration, Choroidal Neovascularization","enrollment":1048},{"nctId":"NCT02307682","phase":"PHASE3","title":"Efficacy and Safety of RTH258 Versus Aflibercept - Study 1","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2014-12-08","conditions":"Neovascular Age-Related Macular Degeneration, Choroidal Neovascularization","enrollment":1775},{"nctId":"NCT03481660","phase":"PHASE3","title":"A Study of the Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2018-07-27","conditions":"Diabetic Macular Edema","enrollment":360},{"nctId":"NCT04047472","phase":"PHASE3","title":"Study of Efficacy and Safety of Brolucizumab vs. Aflibercept in Chinese Patients With Neovascular Age-Related Macular Degeneration","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2019-11-29","conditions":"Neovascular Age-Related Macular Degeneration","enrollment":397},{"nctId":"NCT04820452","phase":"PHASE2","title":"A Study of IBI302 in Patients With nAMD","status":"COMPLETED","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2021-04-28","conditions":"Neovascular Age-related Macular Degeneration","enrollment":231},{"nctId":"NCT01940887","phase":"PHASE3","title":"A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Either Avastin® or Eylea® Compared to Avastin® or Eylea® Monotherapy","status":"TERMINATED","sponsor":"Ophthotech Corporation","startDate":"2014-05","conditions":"Age-Related Macular Degeneration","enrollment":645},{"nctId":"NCT02387957","phase":"PHASE2","title":"A 24 Month Phase 2a Open Label, Randomized Study of Avastin®, Lucentis®, or Eylea® (Anti-VEGF Therapy) Administered in Combination With Fovista® (Anti-PDGF BB Pegylated Aptamer)","status":"TERMINATED","sponsor":"Ophthotech Corporation","startDate":"2016-04-26","conditions":"Age-Related Macular Degeneration","enrollment":63},{"nctId":"NCT03709745","phase":"PHASE4","title":"Eylea and Lucentis for Macular Edema in Branch Retinal Vein Occlusion","status":"COMPLETED","sponsor":"St. Erik Eye Hospital","startDate":"2018-10-18","conditions":"Branch Retinal Vein Occlusion with Macular Edema","enrollment":110},{"nctId":"NCT05473715","phase":"PHASE4","title":"A Study to Learn How Well Aflibercept Injected Into the Eye Works and How Safe it is When Given in Customized Treatment Intervals in Patients With an Eye Disease Called Neovascular Age-related Macular Degeneration After Start of Treatment","status":"TERMINATED","sponsor":"Bayer","startDate":"2023-04-25","conditions":"Neovascular (Wet) Age-related Macular Degeneration","enrollment":3},{"nctId":"NCT04058067","phase":"PHASE3","title":"To Compare Brolucizumab to Aflibercept in Chinese Patients With Visual Impairment Due to Diabetic Macular Edema","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2019-08-23","conditions":"Diabetic Macular Edema","enrollment":266},{"nctId":"NCT04603937","phase":"PHASE3","title":"A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME)","status":"TERMINATED","sponsor":"Kodiak Sciences Inc","startDate":"2020-09-30","conditions":"Diabetic Macular Edema","enrollment":459},{"nctId":"NCT04611152","phase":"PHASE3","title":"A Trial to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME)","status":"TERMINATED","sponsor":"Kodiak Sciences Inc","startDate":"2020-09-30","conditions":"Diabetic Macular Edema","enrollment":460},{"nctId":"NCT05275205","phase":"PHASE2","title":"Safety, Tolerability, and Efficacy Study of UBX1325 in Patients With Neovascular Age-Related Macular Degeneration (ENVISION)","status":"COMPLETED","sponsor":"Unity Biotechnology, Inc.","startDate":"2022-03-02","conditions":"Neovascular Age-related Macular Degeneration","enrollment":51},{"nctId":"NCT04740905","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Branch Retinal Vein Occlusion","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2021-03-02","conditions":"Macular Edema, Branch Retinal Vein Occlusion","enrollment":553},{"nctId":"NCT04740931","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Central Retinal or Hemiretinal Vein Occlusion","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2021-03-02","conditions":"Macular Edema, Central Retinal Vein Occlusion, Hemiretinal Vein Occlusion","enrollment":729},{"nctId":"NCT04469595","phase":"PHASE4","title":"A Study of Intravitreal ILUVIEN® Implant as Baseline Therapy in Patients With Early Diabetic Macular Edema (DME)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alimera Sciences","startDate":"2020-08-31","conditions":"Diabetic Macular Edema","enrollment":300},{"nctId":"NCT06391411","phase":"NA","title":"Effect of Micronutrient Supplementation on the Intestinal Microbiota in Patients With Age-related Macular Degeneration - The Gut-Retina-axis Study","status":"COMPLETED","sponsor":"Azienda Ospedaliero-Universitaria Careggi","startDate":"2021-03-01","conditions":"Age-Related Macular Degeneration","enrollment":45},{"nctId":"NCT04049266","phase":"PHASE2, PHASE3","title":"A Study to Evaluate the Efficacy and Safety of KSI-301, an Anti-VEGF Antibody Biopolymer Conjugate, Versus Aflibercept in Patients With Neovascular (Wet) Age-Related Macular Degeneration.","status":"TERMINATED","sponsor":"Kodiak Sciences Inc","startDate":"2019-10-08","conditions":"Wet Macular Degeneration","enrollment":559},{"nctId":"NCT03630315","phase":"PHASE1","title":"CLN-0046: Treatment of AMD Subjects With OTX-TKI","status":"COMPLETED","sponsor":"Ocular Therapeutix, Inc.","startDate":"2019-02-18","conditions":"Neovascular Age-related Macular Degeneration","enrollment":29},{"nctId":"NCT04964089","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD)","status":"COMPLETED","sponsor":"Kodiak Sciences Inc","startDate":"2021-06-23","conditions":"Wet Age-related Macular Degeneration","enrollment":557},{"nctId":"NCT05403749","phase":"PHASE2","title":"A Study of Longer Interval of IVT IBI302 in Subjects With nAMD","status":"COMPLETED","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2022-06-29","conditions":"Neovascular Age-related Macular Degeneration","enrollment":132}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":231,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["IAI","Eylea","Eylea, VEGF Trap-Eye","IAI; EYLEA®; BAY86-5321; VEGF Trap-Eye","Intravitreal Eylea injection"],"phase":"marketed","status":"active","brandName":"Intravitreal Aflibercept Injection","genericName":"Intravitreal Aflibercept Injection","companyName":"Ophthalmic Consultants of Boston","companyId":"ophthalmic-consultants-of-boston","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Aflibercept is a soluble decoy receptor that binds vascular endothelial growth factor (VEGF) and placental growth factor (PlGF), preventing their interaction with endogenous receptors and reducing abnormal blood vessel growth in the eye. Used for Neovascular (wet) age-related macular degeneration, Macular edema following retinal vein occlusion, Diabetic macular edema.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}